The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.

Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting CKD using the latter’s AI-driven ...

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

Genentech has announced an investment exceeding $700m to establish its first East Coast manufacturing facility in North ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for ...

Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...